An opportunity exists to register interest for the purchase of Series A Preferred Stock (Shares) in Aerami Therapeutics Holdings, Inc.
The opportunity is open solely to investors who qualify as “accredited investors,” as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”). This private placement is exempt from registration under the Securities Act and applicable state securities laws.
Aerami is developing novel inhaled therapies for the treatment of chronic diseases. https://aerami.com/inhalation-technology/. Its platform is designed to overcome limitations of injectable and other inhaled formulation technologies for managing chronic diseases, and ultimately improve treatment efficacy and patient experience.
Aerami is advancing a diverse pipeline of inhaled therapies for the treatment of chronic diseases in the endocrinology, respiratory and cardiovascular space.
The initial focus was on diabetes. Areami developed a soft mist inhaled human insulin for patients with type 1 and 2 diabetes which has demonstrated a faster onset and similar profile to injectable insulin in clinical studies. In addition,it has formulated a pre-meal rapid acting Glucagon like Peptide Analog (GLP-1) to help patients with type 2 diabetes keep their postprandial hyperglycemia (hyperglycemia after meals) under control.
Aerami is now broadening its focus beyond diabetes to include additional chronic conditions that could potentially achieve better treatment efficiency from the patient friendly administration afforded by the AFINA Inhaler. Its pipeline therapies target hypoparathyroidism, osteoporosis and human growth hormone deficiency (HGH), which could benefit from the frequent pulsatile administration of inhaled parathyroid hormone and HGH.
For more information, click on the Register Interest button and you will be contacted by an advisor to the Issuer.